Showing results (131-140 of 174) with videos related to

Sort By:
Pageof 18
Nature Medicine|February 6, 2024
MYC targeting by OMO-103 in solid tumors: a phase 1 trialElena Garralda, Marie-Eve Beaulieu, Víctor Moreno, et al.
Nature Communications|June 13, 2019
LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapyMónica Pascual-García, Ester Bonfill-Teixidor, Ester Planas-Rigol, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2021
High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast CancerMònica Sánchez-Guixé, Cinta Hierro, José Jiménez, et al.
Clinical and Translational Science|February 16, 2024
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumorsDebbie Robbrecht, Jean-Jacques Grob, Oliver Bechter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 29, 2018
Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic TherapiesRodrigo A Toledo, Elena Garralda, Maria Mitsi, et al.
Communications Biology|November 26, 2025
Histology-informed microstructural diffusion simulations for MRI cancer characterisation-the Histo-μSim frameworkAthanasios Grigoriou, Carlos Macarro, Marco Palombo, et al.
Nature Communications|November 18, 2024
Generation of chimeric antigen receptor T cells targeting p95HER2 in solid tumorsMacarena Román Alonso, Ariadna Grinyó-Escuer, Santiago Duro-Sánchez, et al.
Future Oncology (London, England)|October 6, 2022
SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNAAleix Prat, Luis Paz-Ares, Manel Juan, et al.
The Oncologist|April 24, 2025
Barriers to publishing early phase clinical trials: the oncologists' perspectiveMerel J J Lucassen, Pedro Bergmann, Olga Husson, et al.
Endocrine-Related Cancer|November 27, 2014
Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibilityRodrigo A Toledo, Roxanne Hatakana, Delmar M Lourenço, et al.
Pageof 18